COL18A1 and hepatocellular carcinoma: L02 was used as control with an antiangiogenesis evaluating in vitro and in vivo experiment system to study the effects of recombinant human endostatin (endostar) on human HCC cell line HepG2-induced angiogenesis-related biological behaviors of HUVECs, which could provide theoretical and experimental evidence for endostar being used as an antiangiogenesis drug in HCC treatment.